Gemzar and Fluid retention - a phase IV clinical study of FDA data

Summary:

Fluid retention is reported as a side effect among people who take Gemzar (gemcitabine hydrochloride), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Decadron, and have Breast cancer metastatic.

The phase IV clinical study analyzes which people have Fluid retention when taking Gemzar. It is created by eHealthMe based on reports of 20,184 people who have side effects when taking Gemzar from the FDA, and is updated regularly.

What is Gemzar?

Gemzar has active ingredients of gemcitabine hydrochloride. It is often used in pancreatic carcinoma. eHealthMe is studying from 20,315 Gemzar users. Check the latest studies of Gemzar.

What is Fluid retention?

Fluid retention (an abnormal accumulation of fluid in the blood) is found to be associated with 1,702 drugs and 2,443 conditions by eHealthMe. Check the latest studies of Fluid retention.

On Jul, 16, 2026

20,184 people reported to have side effects when taking Gemzar.
Among them, 57 people (0.28%) have Fluid retention.

Among these 57 people:

How long have people been on Gemzar when they have Fluid retention? *

What is the gender of people who have Fluid retention when taking Gemzar? *

female: 55.36 %
male: 44.64 %

What is the age of people who have Fluid retention when taking Gemzar? *

What are other drugs people take besides Gemzar? *

What are other side effects people have besides Fluid retention? *

Fatigue (feeling of tiredness): 12 people, 21.05%
Dyspnea (difficult or laboured breathing): 12 people, 21.05%
Thrombocytopenia (decrease of platelets in blood): 11 people, 19.30%
Pleural Effusion (water on the lungs): 9 people, 15.79%
Acute Kidney Failure: 9 people, 15.79%
Nausea (feeling of having an urge to vomit): 8 people, 14.04%
Ascites (accumulation of fluid in the abdominal cavity): 8 people, 14.04%
Oedema Peripheral (superficial swelling): 8 people, 14.04%
Back Pain: 8 people, 14.04%
Weight Increased: 7 people, 12.28%

What are the existing conditions these people have? *

Breast Cancer Metastatic: 6 people, 10.53%
Lung Cancer - Non-Small Cell (lung cancer): 4 people, 7.02%
Nausea (feeling of having an urge to vomit): 3 people, 5.26%
Pancreatic Carcinoma Recurrent (pancreatic cancer - recurrent): 3 people, 5.26%
Pancreatic Carcinoma Metastatic (pancreatic cancer- metastatic): 3 people, 5.26%
Ovarian Adenocarcinoma (cancer tumour of ovary): 3 people, 5.26%
Ovarian Cancer (cancer of ovary): 2 people, 3.51%
Breast Cancer Female: 2 people, 3.51%
Lymphoma (cancer that begins in immune system cells): 2 people, 3.51%
Adenocarcinoma Pancreas (cancer of pancreas): 2 people, 3.51%

* Approximation only. Some reports may have incomplete information.

Do you take Gemzar and have Fluid retention?

- Check whether Fluid retention is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Gemzar:

Gemzar (20,315 reports)

Fluid retention treatments and more:

Fluid retention (79,660 reports)

Browse all side effects of Gemzar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Fluid retention:

Fluid retention (1,702 drugs)

Browse all the conditions that are associated with Fluid retention:

Fluid retention (2,443 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on gemcitabine hydrochloride (the active ingredients of Gemzar) and Gemzar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.